Our Performance

TABLE OF CONTENTS

>	Sustainable, Increasingly Diversified Product Lines
>	Sustained Revenue Growth
>	Strong Leverage, Steadily Increasing Returns
>	Most-Prescribed Products By Indication
>	Non-GAAP EPS
>	Cash Generation

Includes currently marketed products and follow on products (Synvisc/Synvisc-One, Renagel/Renvela) plus Mozobil.
* Includes Oncology and Thyrogen